Close cardiovascular monitoring during the early stages of treatment for patients receiving immune checkpoint inhibitors
Bron
Pharmaceuticals - ISSN 1424-8247-17:7 (2024) p. 1-12
Intermediate molecular phenotypes to identify genetic markers of anthracycline-induced cardiotoxicity risk
Bron
Cells - ISSN 2073-4409-12:15 (2023) p. 1-28
Extensive CArdioVAscular characterization and follow-up of patients receiving immune checkpoint inhibitors : a prospective multicenter study
Bron
Pharmaceuticals - ISSN 1424-8247-16:4 (2023) p. 1-14
First evidence of activity of enfortumab vedotin on brain metastases in urothelial cancer patients
Bron
Pharmaceuticals - ISSN 1424-8247-16:3 (2023) p. 1-8
Humoral and cellular immune responses against SARS-CoV-2 after third dose BNT162b2 following double-dose vaccination with BNT162b2 versus ChAdOx1 in patients with cancer
Bron
Clinical cancer research - ISSN 1078-0432-29:3 (2023) p. 635-646